AEGLEA BIOTHERAPEUTICS INC. overview

Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD PR Newswire WALTHAM, Mass., Nov. 27, 2023 Company will begin trading on Nasdaq under trading symbol "SYRE" effective November 28, 2023 Biotechnology leader Cameron Turtle , DPhil, appointed as Chief Executive Officer and Member of the Board of Directors alongside industry veterans...

Aeglea BioTherapeutics Announces Grants of Inducement Awards PR Newswire WALTHAM, Mass., Nov. 22, 2023 WALTHAM, Mass. , Nov. 22, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that Aeglea's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase...

Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire WALTHAM, Mass., Nov. 9, 2023 Continued progress across the Company's potentially best-in-class inflammatory bowel disease (IBD) portfolio SPY001, a half-life extended anti-α4β7 antibody, is on track for an expected IND filing in the first half of 2024, with interim healthy volunteer, proof of concept pharmacokinetic data expected year-end 2024 SPY002, a half-life extended anti-TL1A...

Aeglea BioTherapeutics Announces Grants of Inducement Awards PR Newswire WALTHAM, Mass., Nov. 3, 2023 WALTHAM, Mass. , Nov. 3, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that Aeglea's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Aeglea BioTherapeutics (NASDAQ: AGLE) PR Newswire NEW YORK, Nov. 1, 2023 NEW YORK , Nov. 1, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) on behalf of the company's shareholders. The investigation seeks to determine whether Aeglea's directors breached their fiduciary duties in connection with recent corporate actions that have caused a...

Aeglea BioTherapeutics to Participate in Upcoming November Investor Conferences PR Newswire WALTHAM, Mass., Oct. 30, 2023 WALTHAM, Mass. , Oct. 30, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that management will participate in the following investor conferences: Guggenheim 5 th Annual...

Aeglea BioTherapeutics Announces Grants of Inducement Awards PR Newswire WALTHAM, Mass., Oct. 2, 2023 WALTHAM, Mass. , Oct. 2, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that, Aeglea's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase...

Aeglea BioTherapeutics to Participate in Upcoming September Conference PR Newswire WALTHAM, Mass., Sept. 14, 2023 WALTHAM, Mass. , Sept. 14, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that management will participate in the Stifel 2023 Immunology & Inflammation Virtual Summit. Chief Operating...